Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), final data from a Phase 3 clinical trial show. The results, “Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer,” were published in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) annual meeting — held virtually due to the COVID-19 pandemic. “Overall survival is a critical…
You must be logged in to read/download the full post.
The post Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds appeared first on BioNewsFeeds.